Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
19 December, 2014 04:32 IST
Protonix settlement a blow to Sun Pharma's near-term acquisition plans
Source: IRIS | 13 Jun, 2013, 10.27AM
Comments  |  Post Comment

Sun Pharmaceutical Industries said Wednesday the company settled litigation pending in the United States District Court, District of New Jersey (Court) regarding Sun Pharma (Q,N,C,F)* subsidiary's generic pantoprazole. Sun Pharma will pay USD 550 million to Pfizer Inc and Atlanta Pharma AG as a part of this settlement. It will continue to sell its generic pantoprazole in the U.S.

In 2005, Wyeth and Altana had filed a patent infringement suit against Sun after it filed its ANDA for Pantoprazole. Sun launched its generic Pantoprazole in the US on Jan. 30, 2008 at risk. In April 2010, a jury had determined that Altana's patent was valid. Wyeth had sought USD 960 million for the so called infringement. The Protonix patent had expired in January 2011. On Jun. 3, 2013, the court began a jury trial to assess the amount of past damages that Sun Pharma owed for infringing Altana's now expired patent. The settlement has effectively neutralised the ongoing litigation. Sun has already provided for USD 107 million in Q2FY13.

Commenting on the development, ICICIdirect said, ''As the settlement amount is unprecedented, the stock is likely to witness knee-jerk reaction in the near term. However, the event was not entirely unexpected. Sun will have to shell out Rs 30 billion out of its cash pile of Rs 54 billion as on Mar. 31, 2013, thus effectively putting its immediate acquisition plans in jeopardy. We have cut our FY14E and FY15E EPS estimates by Rs 27 and Rs 5, respectively, owing to a dent in other income (treasury income). Our revised target price now stands at Rs  976 i.e. 23x FY15E (revised) EPS of Rs 42.4. We maintain Hold. Any swift correction can be used as an opportunity to re-enter the stock as all other strongholds remain intact.''

It has maintained 'Hold' on Sun Pharmaceuticals with target price of Rs 976 as against current market price (CMP) of Rs 981 in its report.

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Punj Lloyd gets FIPB nod for manufacture of defence items - 18-Dec-2014 19:17
FIIs can invest up to 100% in Crompton Greaves: RBI - 18-Dec-2014 18:57
FIIs can invest up to 49% in Tree House Education: RBI - 18-Dec-2014 18:40
Logistics companies to be biggest beneficiaries of GST: Allcargo Logistics - 18-Dec-2014 16:40
IVRCL inks pact with Utico FZC to sell equity stake in its arm - 18-Dec-2014 15:46
Indusind Bank allots 51,947 shares under ESOS - 18-Dec-2014 15:25
Snapdeal ties up with Hero MotoCorp - 18-Dec-2014 13:46
Zicom launches `Ziman` new mobile application - 18-Dec-2014 13:37
Nomura cuts target on RIL; maintains `Buy` - 18-Dec-2014 12:35
Emkay maintains `Buy` on Ashoka Buildcon - 18-Dec-2014 12:17
RPP Infra Projects bags new contract worth Rs 495.46 mn - 18-Dec-2014 11:55
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer